Latest news with #FrostSullivan
Yahoo
a day ago
- Business
- Yahoo
Frost & Sullivan Released Report: "2025 China Pharmaceutical CDMO Industry Insight Blue Book"
Shanghai, China--(Newsfile Corp. - June 19, 2025) - Frost & Sullivan released the "2025 China Pharmaceutical CDMO Industry Insight Blue Book", a comprehensive analysis of the evolution and strategic trajectory of China's pharmaceutical Contract Development and Manufacturing Organization (CDMO) sector. Rooted in an in-depth examination of market dynamics, technological innovation, and global competitiveness, the report elucidates how China's CDMO industry is reshaping the global pharmaceutical value chain through specialized services, operational agility, and cutting-edge capabilities. (To read the Blue Book, go here: "2025 China Pharmaceutical CDMO Industry Insight Blue Book " highlights the following: The Core Position of the CDMO Sector: How CDMOs support pharmaceutical companies across the entire drug development and manufacturing value chain. Four Development Stages of China's CDMO Industry: From Policy Liberalization to Global Competition, tracing the evolution and growth of China's CDMO sector. Dual-Engine Phase of Scale Expansion and Domain Segmentation: The expansion and specialization trends within China's CDMO industry. Sub-sectors of CDMO: Detailed insights into Small Molecule, Peptide, Antibody, ADC, and CGT CDMO segments. Multi-Point Growth Pattern: The diverse growth points and strategic developments of China's CDMO industry. Introduction to Selected Chinese CDMOs: Showcasing leading CDMOs in China and their contributions to the industry, including BiBo Pharma, Healthnice, Porton Pharma, ChemExpress, OBiO Technology, Pharmaron, PharmaBlock, Yaohai Bio-Pharma, uBriGene, Intellective Bio, Chinese Peptide, and TOT Biopharm. The CDMO Sector Holds a Core Position in the Pharmaceutical Industry As a major part of the outsourcing pharmaceutical service industry, CDMOs support pharmaceutical companies across the entire chain, from drug discovery to market launch, and from process development to large-scale manufacturing. They rely on large-scale production capacity and high value-added R&D and manufacturing processes. As a result, CDMOs have become key partners and hold a core position in China's pharmaceutical industry. Demand Drives Expansion and Subdivision of CDMOs The continued evolution of global demand for biopharmaceutical R&D and manufacturing is pushing China's CDMO industry into a dual-engine phase of scale expansion and domain segmentation. On one hand, the increasing technical complexity of emerging areas such as CGT, ADCs, and nucleic acid drugs is driving strong demand for specialized CDMO services. On the other hand, traditional segments like small molecule drugs continue to expand production capacity due to process optimization and steady market demand. At the same time, differentiated demands from pharmaceutical companies are accelerating the diversification of service models. Biopharma companies tend to divest non-core manufacturing functions to focus on innovative pipelines, thereby driving CDMOs toward high-end process development. Biotech firms, constrained by resources, increasingly rely on one-stop services that provide full-cycle support from target validation to IND filing, prompting the rise of full-chain CDMO platforms. In response, Chinese CDMOs are using technological deployment and service model innovation to build entry barriers in niche areas while using large-scale production capacity to capture global orders, thus establishing a dual-path development model of "high-end breakthroughs + foundational consolidation."。 Four Development Stages : Policy, Technology, and Capital-Driven the Closed-Loop Growth of China's CDMO Industry China's pharmaceutical CDMO industry has gone through four key stages: policy liberalization, technology transfer, capital-driven growth, and global competition. The sector has moved from the early phase of reliant on foreign technology and policy incentives to a more advanced stage defined by deep technical expertise, global production layout, and integrated ecosystems. On the policy side, the implementation of the MAH system, stricter GMP standards, and medical insurance reform have pushed pharmaceutical companies to separate their manufacturing functions, creating strong demand for CDMO services. On the technology side, advancements in continuous flow chemistry, enzymatic catalysis, and AI-based drug design have increased the added value of services. On the capital side, funding has fueled the rise of emerging fields. The industry now follows a closed-loop development model: policy-driven demand-technology-driven service upgrades-capital-driven expansion-global ecosystem integration. This reflects a shift in China's CDMO sector from rapid scale expansion to high-quality development. A Multi-Front Development Trend of China's CDMO Industry Chinese CDMO enterprises are strategically advancing vertically integrated service capabilities across the pharmaceutical value chain through organic growth and strategic mergers, aligning with China's push for high-quality industrial development. As sector competition intensifies, differentiation through niche specialization has become critical. To address global capacity imbalances and optimize biologics production economics, CDMOs are prioritizing operational efficiency upgrades and smart manufacturing adoption. Leading players are simultaneously executing multi-pronged globalization strategies: establishing GMP-compliant facilities in key overseas markets to secure long-term international competitiveness, while deepening technological moats through specialized R&D investments in advanced modalities. This dual approach enables breakthroughs in traditional competitive frameworks through differentiated capabilities. Global capacity networks are being rapidly expanded in overseas production hubs and acquisitions of internationally certified manufacturers, forming interconnected supply chains aligned with global pharmaceutical collaboration systems. Simultaneously, innovative CRDMO models are integrating value chain resources to create end-to-end service ecosystems spanning drug discovery to commercial manufacturing. Case studies including BiBo Pharma, Porton Pharma, Healthnice, ChemExpress, OBiO Technology, Pharmaron, PharmaBlock, Yaohai Bio-Pharma, uBriGene, Intellective Bio and Chinese Peptide exemplify the diversified growth trajectories shaping China's CDMO landscape. These enterprises demonstrate how strategic focus on technological innovation, operational excellence, and global integration is redefining the sector's competitive dynamics. About Frost & Sullivan Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 60 years, Frost & Sullivan has been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Media ContactContact: Qian LiCompany Name: Frost & SullivanWebsite: To view the source version of this press release, please visit
Zawya
2 days ago
- Business
- Zawya
Ericsson ranks highest in Frost Radar™ 5G Network Infrastructure Market Report for fifth consecutive year
Ericsson has been recognized as a forefront leader in Frost & Sullivan's "Frost Radar: 5G Network Infrastructure, 2025" report for the fifth year in a row. This recognition highlights Ericsson's commitment to innovation and growth, as well as its ability to meet the evolving needs of communications service providers (CSPs) and enterprises worldwide. Frost & Sullivan independently plotted the top 23 companies in the Frost Radar analysis among over 100 global participants. These companies lead or innovate in various segments of the market. The report highlights Ericsson's contributions to the 5G landscape, cementing its position as a key player in shaping the future of mobile technologies. For the past five years, the company's innovative solutions have been acknowledged in this independent analysis as the leading portfolio for 5G network infrastructure. Ericsson's comprehensive portfolio includes products and solutions covering traditional radio access network (RAN), open and virtual RAN, core and edge networks, and private networks. Frost & Sullivan anticipates a shift towards open and virtual RAN across the industry, and notes that Ericsson's foray into Open RAN solutions 'will help make this a reality, especially since its first few customers are large and influential CSPs.' The use of artificial intelligence (AI) to automate network offerings and promote network APIs further demonstrates Ericsson's innovative approach to mobile networks, according to the Frost Radar report. Per Narvinger, Executive Vice President and Head of Business Area Networks at Ericsson, says: "Our consistent top ranking in the Frost Radar report shows our dedication to innovation in a dynamic market. By focusing on customer-centric solutions and using advanced technologies like AI and intent-driven automation, we are enhancing network programmability. This enables differentiated connectivity and supports our customers in their journey toward autonomous networks.' 'Leading the global 5G network infrastructure market for five consecutive years is a remarkable achievement,' says Troy Morley, Senior Industry Analyst, Frost & Sullivan Information, Communications and Technologies. 'Ericsson has consistently outperformed traditional competitors and fended off emerging entrants in this challenging market. Despite its size, the market experiences fluctuations, with periods of growth and decline. Ericsson has adeptly navigated these complexities by evolving its portfolio, ensuring its own financial stability while maintaining its leadership position.' With customers in more than 175 countries, Ericsson has proven its ability to scale its innovations globally with 2G, 3G, 4G, and now 5G, according to the report, adding that Ericsson's dedication to research and development (R&D) – with 21.6 percent of its revenue invested in 2024 alone – shows its resolve to stay ahead in an ever-evolving industry. 'Moreover, the company's strategic adjustments and focus on profitability have positioned it for sustained growth and stability,' Morley says. The acquisitions of Cradlepoint in 2020 and Vonage in 2022 have expanded Ericsson's reach into the enterprise market, complementing its robust CSP and industry partner base. The Frost Radar report highlights the growth potential in private 4G and 5G networks, where Ericsson is well-positioned to collaborate with CSPs and industry partners to continue to lead the market in these enterprise opportunities. Additionally, as energy efficiency becomes increasingly critical, Ericsson has focused on designing hardware products that are smaller, lighter, and more energy-efficient, while also rolling out a number of software solutions to optimize network resources. The full range is available to meet the growing demand for sustainable technology. The Frost Radar measures growth rates in addition to absolute revenue and combines them with several other factors to measure companies' performance along the Growth Index. The Frost Radar measures innovation for each company by assessing its product portfolio, the scalability of its innovations, the efficacy of its R&D strategy, and several other factors. Ericsson's 5G network infrastructure portfolio comprises 5G RAN, 5G Core, and 5G Transport that address all aspects of 5G deployments – from providing low latency and higher bandwidth to ensuring instant response times for users and lower power consumption per delivered gigabyte for CSPs. Ericsson's 5G network offering also includes Ericsson Radio System, Cloud RAN, Ericsson 5G Advanced, network automation, and Differentiated Connectivity. CSPs are empowered with 5G solutions that enable the modular approach when switching to the cloud-native 5G network or expanding their network for new business opportunities. Ericsson's private 5G solutions are tailored to drive digitalization in industry 4.0 and beyond through secure and powerful 4G LTE and 5G standalone (SA) connectivity. This enables enterprise organizations to improve efficiencies, visibility, and safety in their operations by leveraging the reliability, flexibility, low latency, and security that Ericsson's best-in-class radio portfolio enables. ABOUT ERICSSON: Ericsson's high-performing networks provide connectivity for billions of people every day. For nearly 150 years, we've been pioneers in creating technology for communication. We offer mobile communication and connectivity solutions for service providers and enterprises. Together with our customers and partners, we make the digital world of tomorrow a reality.
Al Bawaba
3 days ago
- Business
- Al Bawaba
Ericsson ranks highest in Frost Radar™ 5G Network Infrastructure Market Report for fifth consecutive year
Ericsson has been recognized as a forefront leader in Frost & Sullivan's "Frost Radar: 5G Network Infrastructure, 2025" report for the fifth year in a row. This recognition highlights Ericsson's commitment to innovation and growth, as well as its ability to meet the evolving needs of communications service providers (CSPs) and enterprises worldwide. Frost & Sullivan independently plotted the top 23 companies in the Frost Radar analysis among over 100 global participants. These companies lead or innovate in various segments of the market. The report highlights Ericsson's contributions to the 5G landscape, cementing its position as a key player in shaping the future of mobile technologies. For the past five years, the company's innovative solutions have been acknowledged in this independent analysis as the leading portfolio for 5G network infrastructure. Ericsson's comprehensive portfolio includes products and solutions covering traditional radio access network (RAN), open and virtual RAN, core and edge networks, and private networks. Frost & Sullivan anticipates a shift towards open and virtual RAN across the industry, and notes that Ericsson's foray into Open RAN solutions 'will help make this a reality, especially since its first few customers are large and influential CSPs.' The use of artificial intelligence (AI) to automate network offerings and promote network APIs further demonstrates Ericsson's innovative approach to mobile networks, according to the Frost Radar report. Per Narvinger, Executive Vice President and Head of Business Area Networks at Ericsson, says: "Our consistent top ranking in the Frost Radar report shows our dedication to innovation in a dynamic market. By focusing on customer-centric solutions and using advanced technologies like AI and intent-driven automation, we are enhancing network programmability. This enables differentiated connectivity and supports our customers in their journey toward autonomous networks.' 'Leading the global 5G network infrastructure market for five consecutive years is a remarkable achievement,' says Troy Morley, Senior Industry Analyst, Frost & Sullivan Information, Communications and Technologies. 'Ericsson has consistently outperformed traditional competitors and fended off emerging entrants in this challenging market. Despite its size, the market experiences fluctuations, with periods of growth and decline. Ericsson has adeptly navigated these complexities by evolving its portfolio, ensuring its own financial stability while maintaining its leadership position.' With customers in more than 175 countries, Ericsson has proven its ability to scale its innovations globally with 2G, 3G, 4G, and now 5G, according to the report, adding that Ericsson's dedication to research and development (R&D) – with 21.6 percent of its revenue invested in 2024 alone – shows its resolve to stay ahead in an ever-evolving industry. 'Moreover, the company's strategic adjustments and focus on profitability have positioned it for sustained growth and stability,' Morley says. The acquisitions of Cradlepoint in 2020 and Vonage in 2022 have expanded Ericsson's reach into the enterprise market, complementing its robust CSP and industry partner base. The Frost Radar report highlights the growth potential in private 4G and 5G networks, where Ericsson is well-positioned to collaborate with CSPs and industry partners to continue to lead the market in these enterprise opportunities. Additionally, as energy efficiency becomes increasingly critical, Ericsson has focused on designing hardware products that are smaller, lighter, and more energy-efficient, while also rolling out a number of software solutions to optimize network resources. The full range is available to meet the growing demand for sustainable technology. The Frost Radar measures growth rates in addition to absolute revenue and combines them with several other factors to measure companies' performance along the Growth Index. The Frost Radar measures innovation for each company by assessing its product portfolio, the scalability of its innovations, the efficacy of its R&D strategy, and several other factors.
Associated Press
09-06-2025
- Business
- Associated Press
Frost & Sullivan: iRegene Therapeutics Honored as '2025 Forbes China Leading Enterprises in Industry Development'
Recently, The '2025 Frost & Sullivan China Entrepreneurs Annual Conference and Forbes China Pioneer Innovators in Industry Development Selection Gala Evening of Honor,' jointly organized by Frost & Sullivan and Forbes China, was successfully held at Regent Shanghai on The Bund. Amid the global trend of industrial innovation, the results of the '2025 Pioneer Innovators in Industry Development' selection jointly initiated by Forbes China and Frost & Sullivan were officially announced. iRegene Therapeutics was honored as one of Forbes China's 2025 Leading Enterprises in Industry Development. iRegene is pioneering the future of regenerative medicine with its AI-powered, chemically induced cell therapy platform. By combining cutting-edge technology, a robust R&D ecosystem, and a globally experienced leadership team, iRegene is redefining allogeneic therapies to make them safer, more effective, and broadly accessible. This recognition highlights iRegene's continued leadership in innovation and its commitment to transforming patient care through next-generation regenerative therapies. iRegene Therapeutics Honored as [2025 Forbes China Leading Enterprises in Industry Development] Aroop Zutshi, Global Managing Partner and Executive Board Director of Frost & Sullivan, and Junyi Guo, General Manager of Business Operations at Forbes China, jointly presented the 2025 Forbes China Leading Enterprises in Industry Development award. Dr. Jun Wei, Chairman of iRegene Therapeutics, was invited to attend the gala. AI-Driven Chemical-Induced Cell Therapy: Reshaping the Future of Accessible Cell Therapy Since its establishment in 2017, iRegene Therapeutics has remained committed to addressing unmet clinical needs through the development of next-generation cell therapies. With a focus on chemically induced, universal cell therapy products, iRegene aims to deliver transformative treatments for patients with currently incurable diseases. iRegene Therapeutics has a proprietary, AI-based platform for screening chemical compounds to modify specific cellular functions. The platform leverages induced pluripotent stem cells (iPSCs) to enhance treatment potential. By combining compounds to form a chemically induced culture medium, the 'AI+Chem' platform can efficiently and precisely reprogram or optimize a cell's fate and function, thereby enhancing the clinical capabilities of cell therapies. With a focus on the chemical induction system, iRegene has developed a comprehensive research and development (R&D) ecosystem and an international patent system that spans the industry. This ecosystem combines the discovery of 'cell fate determinants', the screening of chemical inducers and the validation of cellular function. The system does not use viral vector construction or transgenic methods; the straightforward CMC procedure is cost-efficient. Furthermore, cell transformation and functional optimization are entirely driven by the cells' natural genetic makeup. Transformation is synchronous under chemically enhanced regulation, eliminating the risk of genetic modification. iRegene's pioneering platform has been proven through the positive outcomes of the Phase I clinical trial. In addition, iRegene's executive team has an international perspective, with all members having successful overseas experience in their specialized fields. CEO Dr Wei Jun is a leading expert in regenerative medicine and the induced pluripotent stem cell (iPSC) technology, brings strategic leadership to the company. Chief Medical Officer Dr Cai Meng has extensive experience taking innovative therapies from discovery through clinical development, while Chief Quality Officer Ren Xiang is a senior regulatory expert who provides solid support from IND approval to NDA clearance in China, the US, and other countries. Executive Vice President Emmanuel Montet, formerly Vice President of the Asia-Pacific region at Ipsen, now leads iRegene's global business development and international strategy. To accelerate global clinical translation and commercialization, iRegene places great emphasis on the philosophy of 'cooperation and mutual benefit'. At the end of 2021, iRegene entered a long-term collaboration with Danaher Corporation to co-develop next-generation platforms for clinical application. Under this partnership, Danaher will play an active role in developing multi-directional platforms for future iRegene Therapeutics projects. This will involve supplying advanced detection instruments and technical resources relating to life sciences research, the development of effective compounds and screening, multi-omics cell mechanism research, and multi-substance screening. Danaher will help iRegene Therapeutics to enhance the efficiency of platform construction and its ability to deliver practical solutions. Danaher will also support iRegene Therapeutics in developing distinctive, innovative drug pipelines and establishing a research and production base. This strategic cooperation has recently been elevated to the iRegene – Danaher Joint Innovation Center, which is the world's first 'Joint Innovation Center for Chemically Induced Therapies and Microphysiology Systems'. The center will focus on integrating artificial intelligence (AI)-driven chemically induced cell therapy R&D with microphysiology systems technology. It is committed to accelerating the clinical translation and application of innovative therapies, and providing patients globally with more precise and effective treatment solutions for diseases. Danaher will fully support iRegene Therapeutics' future planning and development, aiming to jointly advance innovative development in China's life sciences research. iRegene's breakthrough technology platform, strategic advantages and dedicated team have secured continuous support from several leading venture capital firms, with cumulative financing reaching nearly 400 million RMB (55.5 million USD). The company is advancing multiple programs through clinical development, targeting a win-win situation for its products and the capital markets alike, while providing patients around the world with next-generation chemically induced cell therapies that can genuinely reverse disease progression. About iRegene Therapeutics iRegene Therapeutics is a biotechnology company committed to becoming a global leader in universal chemical-induced cell therapy. As one of the first companies to harness AI and + chemical induction for the specific functional modification of cells, iRegene offers a safer, more scalable, and cost-effective alternative to traditional gene or cell therapies. Its pipeline targets diseases with high unmet need, including neurodegenerative disorders such as Parkinson's disease and blindness. Through pioneering science, strategic global partnerships, and a visionary leadership team, iRegene is reshaping the future of regenerative medicine — making advanced therapies accessible to patients worldwide. In August 2023, the NMPA approved the commencement of Phase I clinical trials for iRegene's first product: 'Human Dopaminergic Precursor Cell, NouvNeu001'. This product was developed using the 'AI+ Chem' platform. This made it the world's first chemically induced pluripotent stem cell (iPSC)-derived therapy to enter clinical trials. In June 2024, it was approved by the U.S. FDA for overseas clinical trials. Even more groundbreakingly, in March 2024, iRegene's 'Chemical Induction Platform' became the first system ever to be granted exemption by the FDA. The company's second product, NouvNeu003, which is intended for the treatment of early-onset Parkinson's disease, received NMPA approval in December 2023 and entered Phase I clinical trials. Both NouvNeu001 and NouvNeu003 have now completed Phase I trials. The Phase I results demonstrate good safety, tolerability, and encouraging efficacy in improving motor and non-motor symptoms. The Phase II trial for NouvNeu001 began in April 2025. In parallel, iRegene's first-in-class ophthalmic therapy, was granted Orphan Drug Designation (ODD) by the U.S. FDA in March 2024. Media Contact Company Name: Frost & Sullivan Contact Person: Qian Li Email: Send Email Country: China Website:
Yahoo
04-06-2025
- Business
- Yahoo
Dmall and Frost & Sullivan Release White Paper on China's Smart Retail Global Expansion at NRF APAC 2025
SINGAPORE, June 4, 2025 /PRNewswire/ --Dmall ( a leading Chinese retail digitalization solution provider, has released a new white paper in partnership with global consultancy Frost & Sullivan at NRF 2025. The report, titled White Paper on Current Status and Trends of Overseas Expansion for China's Retail Digitalization Enterprises, marks its global premiere. The white paper provides a detailed look into the evolving needs of global retailers and the growing role of Chinese tech providers in driving digital transformation. It highlights how Chinese companies like DMALL are offering cost-effective, scalable solutions built for high-volume, fast-moving markets — and now taking those solutions global. "Retail digital transformation is an inevitable trend," said Gabriel Lu, Partner and Managing Director at Frost & Sullivan Greater China. "Chinese enterprises are helping shape the next phase of global retail innovation — especially with the rise of AI." Dmall has spent the last decade building smart retail infrastructure in China, helping retailers digitize their supply chains and physical stores. Today, the company is applying its experience globally, integrating AI, cloud, and big data to support international retail clients. According to the report, Asia's retail digitalization market is projected to reach USD 13.07 billion by 2029, with a CAGR of 22.5% from 2024 to 2029 — signaling major growth opportunities. "We're committed to accelerating retail innovation worldwide," said Zhang Feng, Co-founder and President of DMALL. "With our technology and experience, we're ready to support retailers in achieving sustainable growth in the AI era." To download the full white paper, please complete the request form. The PDF will be sent to your email. About DMALL Dmall ( founded in 2015, is committed to driving retail innovation through technology, providing digital and intelligent solutions for the global retail industry. As a leading retail digitalization solution provider in Asia, Dmall covers a wide range of business scenarios, serving diverse customer segments and addressing all critical operational needs of retailers. As of December 31, 2024, Dmall provided technical services to 591 clients, such as DFI Retail Group, SM Group and Metro Group, demonstrating the widespread validation of its business model. View original content to download multimedia: SOURCE Dmall Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
